APTO
Price
$1.20
Change
+$0.01 (+0.84%)
Updated
May 3, 11:21 AM EST
TRVN
Price
$0.41
Change
-$0.00 (-0.00%)
Updated
May 3, 11:12 AM EST
Ad is loading...

Compare trend and price APTO vs TRVN

Header iconAPTO vs TRVN Comparison
Open Charts APTO vs TRVNBanner chart's image
Aptose Biosciences
Price$1.20
Change+$0.01 (+0.84%)
Volume$200
CapitalizationN/A
Trevena
Price$0.41
Change-$0.00 (-0.00%)
Volume$154
CapitalizationN/A
View a ticker or compare two or three
APTO vs TRVN Comparison Chart

Loading...

APTODaily Signal changed days agoGain/Loss if shorted
 
Show more...
TRVNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
APTO vs. TRVN commentary
May 03, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APTO is a Hold and TRVN is a Hold.

COMPARISON
Comparison
May 03, 2024
Stock price -- (APTO: $1.19 vs. TRVN: $0.41)
Brand notoriety: APTO and TRVN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APTO: 44% vs. TRVN: 30%
Market capitalization -- APTO: $19.54M vs. TRVN: $7.49M
APTO [@Biotechnology] is valued at $19.54M. TRVN’s [@Biotechnology] market capitalization is $7.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $559.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APTO’s FA Score shows that 0 FA rating(s) are green whileTRVN’s FA Score has 1 green FA rating(s).

  • APTO’s FA Score: 0 green, 5 red.
  • TRVN’s FA Score: 1 green, 4 red.
According to our system of comparison, TRVN is a better buy in the long-term than APTO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APTO’s TA Score shows that 4 TA indicator(s) are bullish while TRVN’s TA Score has 5 bullish TA indicator(s).

  • APTO’s TA Score: 4 bullish, 4 bearish.
  • TRVN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TRVN is a better buy in the short-term than APTO.

Price Growth

APTO (@Biotechnology) experienced а +2.59% price change this week, while TRVN (@Biotechnology) price change was +0.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.38%. For the same industry, the average monthly price growth was -0.41%, and the average quarterly price growth was +1244.61%.

Reported Earning Dates

APTO is expected to report earnings on Aug 10, 2023.

TRVN is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Biotechnology (+5.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for APTO with price predictions.
OPEN
A.I.dvisor published
a Summary for TRVN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
APTO($19.5M) has a higher market cap than TRVN($7.49M). TRVN YTD gains are higher at: -43.290 vs. APTO (-53.150).
APTOTRVNAPTO / TRVN
Capitalization19.5M7.49M260%
EBITDAN/AN/A-
Gain YTD-53.150-43.290123%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
APTO vs TRVN: Fundamental Ratings
APTO
TRVN
OUTLOOK RATING
1..100
328
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVN's Valuation (30) in the Biotechnology industry is in the same range as APTO (40). This means that TRVN’s stock grew similarly to APTO’s over the last 12 months.

TRVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APTO (100). This means that TRVN’s stock grew similarly to APTO’s over the last 12 months.

TRVN's SMR Rating (100) in the Biotechnology industry is in the same range as APTO (100). This means that TRVN’s stock grew similarly to APTO’s over the last 12 months.

TRVN's Price Growth Rating (64) in the Biotechnology industry is in the same range as APTO (95). This means that TRVN’s stock grew similarly to APTO’s over the last 12 months.

TRVN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APTO (100). This means that TRVN’s stock grew similarly to APTO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APTOTRVN
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
APTODaily Signal changed days agoGain/Loss if shorted
 
Show more...
TRVNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AXTI3.030.14
+4.84%
AXT
OSCR18.090.73
+4.21%
Oscar Health
STE206.241.20
+0.59%
STERIS plc
HIBB86.490.35
+0.41%
Hibbett
BMTX1.69-0.06
-3.43%
BM Technologies

TRVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVN has been loosely correlated with ZNTL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVN jumps, then ZNTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVN
1D Price
Change %
TRVN100%
+6.70%
ZNTL - TRVN
38%
Loosely correlated
-1.77%
ABCL - TRVN
37%
Loosely correlated
+1.85%
DARE - TRVN
31%
Poorly correlated
-5.43%
CRBU - TRVN
31%
Poorly correlated
-1.36%
ITRM - TRVN
29%
Poorly correlated
-0.63%
More